Xbrane Biopharma (Sweden) Buy Hold or Sell Recommendation
| XBRANE Stock | SEK 0.36 0.02 5.88% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Xbrane Biopharma AB is 'Strong Sell'. Macroaxis provides Xbrane Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding XBRANE positions. The advice algorithm takes into account all of Xbrane Biopharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Xbrane Biopharma's buy or sell advice are summarized below:
Real Value 0.29 | Hype Value 0.36 | Market Value 0.36 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Xbrane Biopharma AB given historical horizon and risk tolerance towards Xbrane Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Xbrane Biopharma AB, the advice is generated through an automated system that utilizes algorithms and statistical models.
Xbrane |
Execute Xbrane Biopharma Buy or Sell Advice
The Xbrane recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Xbrane Biopharma AB. Macroaxis does not own or have any residual interests in Xbrane Biopharma AB or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Xbrane Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Xbrane Biopharma Trading Alerts and Improvement Suggestions
| Xbrane Biopharma is way too risky over 90 days horizon | |
| Xbrane Biopharma has some characteristics of a very speculative penny stock | |
| Xbrane Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 11.53 M. Net Loss for the year was (188.38 M) with loss before overhead, payroll, taxes, and interest of (18.27 M). | |
| Xbrane Biopharma AB has accumulated about 44.32 M in cash with (219.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company outstanding shares are owned by insiders |
Xbrane Biopharma Returns Distribution Density
The distribution of Xbrane Biopharma's historical returns is an attempt to chart the uncertainty of Xbrane Biopharma's future price movements. The chart of the probability distribution of Xbrane Biopharma daily returns describes the distribution of returns around its average expected value. We use Xbrane Biopharma AB price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Xbrane Biopharma returns is essential to provide solid investment advice for Xbrane Biopharma.
| Mean Return | 1.17 | Value At Risk | -46 | Potential Upside | 40.00 | Standard Deviation | 32.38 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Xbrane Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Xbrane Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Xbrane Biopharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Xbrane Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Xbrane stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.94 | |
β | Beta against NYSE Composite | 3.65 | |
σ | Overall volatility | 31.71 | |
Ir | Information ratio | 0.03 |
Xbrane Biopharma Volatility Alert
Xbrane Biopharma AB is showing large volatility of returns over the selected time horizon. Xbrane Biopharma AB is a potential penny stock. Although Xbrane Biopharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Xbrane Biopharma AB. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Xbrane instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Xbrane Biopharma Fundamentals Vs Peers
Comparing Xbrane Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Xbrane Biopharma's direct or indirect competition across all of the common fundamentals between Xbrane Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Xbrane Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Xbrane Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Xbrane Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Xbrane Biopharma to competition |
| Fundamentals | Xbrane Biopharma | Peer Average |
| Return On Equity | -0.37 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Operating Margin | (4.61) % | (5.51) % |
| Current Valuation | 2.32 B | 16.62 B |
| Shares Outstanding | 27.51 M | 571.82 M |
| Shares Owned By Insiders | 35.23 % | 10.09 % |
| Shares Owned By Institutions | 22.09 % | 39.21 % |
| Price To Earning | (10.92) X | 28.72 X |
| Price To Book | 7.49 X | 9.51 X |
| Price To Sales | 75.09 X | 11.42 X |
| Revenue | 11.53 M | 9.43 B |
| Gross Profit | (18.27 M) | 27.38 B |
| EBITDA | (172.74 M) | 3.9 B |
| Net Income | (188.38 M) | 570.98 M |
| Cash And Equivalents | 44.32 M | 2.7 B |
| Cash Per Share | 5.34 X | 5.01 X |
| Total Debt | 36.48 M | 5.32 B |
| Debt To Equity | 48.90 % | 48.70 % |
| Current Ratio | 1.45 X | 2.16 X |
| Book Value Per Share | 12.99 X | 1.93 K |
| Cash Flow From Operations | (219.61 M) | 971.22 M |
| Earnings Per Share | (7.13) X | 3.12 X |
| Target Price | 136.5 | |
| Number Of Employees | 74 | 18.84 K |
| Beta | 1.37 | -0.15 |
| Market Capitalization | 2.74 B | 19.03 B |
| Total Asset | 688.43 M | 29.47 B |
| Retained Earnings | (29 M) | 9.33 B |
| Working Capital | 64 M | 1.48 B |
| Current Asset | 77 M | 9.34 B |
| Current Liabilities | 13 M | 7.9 B |
| Z Score | 45.0 | 8.72 |
| Net Asset | 688.43 M |
Xbrane Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Xbrane . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Xbrane Biopharma Buy or Sell Advice
When is the right time to buy or sell Xbrane Biopharma AB? Buying financial instruments such as Xbrane Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Xbrane Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Xbrane Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |